查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1993876

醫藥CDMO市場：按服務類型、技術、治療方式、最終用途、國家和地區分類－全球產業分析、市場規模、市場佔有率和預測（2025-2032年）

Pharmaceutical CDMO Market, By Service Type, By Technology, By Therapeutic Modality, By End-Use, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 353 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年，醫藥 CDMO 市值為 1804.1809 億美元，預計從 2025 年到 2032 年將以 7.20% 的複合年成長率成長。

合約研發生產機構 (CDMO) 是一家專業服務供應商，致力於幫助製藥和生物技術公司開發、生產和銷售藥品。 CDMO 提供廣泛的服務，涵蓋製劑開發、製程開發、臨床和商業化生產、分析測試以及包裝等各個環節。透過與 CDMO 合作，企業可以利用其先進技術、法規專業知識和靈活的生產能力，縮短產品上市時間並提高成本效益。 CDMO 不僅僅是服務供應商，更是策略合作夥伴，尤其是在生物製藥和基因療法等複雜治療方法，它們能夠推動創新、確保品質合規並實現永續成長。各國政府和國際組織，例如美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA) 和世界衛生組織 (WHO)，越來越重視國內生產的韌性和品質標準，並積極推動與 CDMO 的合作，以加強供應鏈、支持疫苗生產能力並符合全球公共衛生目標。

醫藥CDMO市場－市場動態

對支持長期醫療保健永續性的先進生物製藥的需求日益成長

對先進生物製藥日益成長的需求是推動製藥生產和外包業務成長的主要動力。這是因為單株抗體、重組蛋白、疫苗和細胞療法等治療方法正擴大被用於治療包括癌症、自體免疫疾病和代謝紊亂在內的複雜慢性疾病。製藥公司正在拓展其生物製藥產品組合以滿足這一需求，而主要市場的監管機構也支持這一發展趨勢。例如，美國食品藥物管理局（FDA）正在積極修訂其指導方針，以加速生物相似藥和先進生物製藥的研發和上市，從而在幫助患者控制成本的同時，提高產品的可及性。

為了滿足持續成長的需求，全球領先的製藥企業正在擴大產能並投資戰略資產。韓國三星生物製劑公司透過收購位於馬裡蘭州的生產設施，增強其生物製藥生產能力並擴大在美國的企業發展，以滿足長期需求。在政策層面，印度等國已宣布大規模計劃以提升其生物製藥能力，其中包括一項為期五年、投資1000億盧比的專項舉措，旨在將印度打造成為全球生物製藥和生物類似藥生產中心。這些公私合作的協同效應反映了生物製藥療法如何塑造全球永續醫療保健的優先事項。

醫藥CDMO市場－市場區隔分析：

全球醫藥CDMO市場按服務類型、技術、治療方式、最終用途和地區進行細分。

根據服務類型，市場可分為五大類：藥物發現支援服務、分析和法規支援、臨床生產、商業化生產以及包裝和序列化服務。商業化生產在市場中扮演核心角色，因為它能夠提供藥物完成臨床開發階段後，申辦者最迫切需要的大規模生產能力。像龍沙（Lonza）這樣的公司就體現了這一領域的重要性。預計到2025年，該公司核心的CDMO業務（專注於小分子和生物製劑平台的商業化生產）銷售額將成長至65億瑞士法郎，佔總收入的很大一部分，並推動利潤率的提升。政府正在推行的各項舉措，例如美國FDA的「PreCheck」舉措，正透過簡化設施審查和加強生產基礎設施，優先考慮擴大國內生產規模，這凸顯了商業化生產在保障可靠供應和市場進入方面發揮的關鍵作用。

根據治療方式，市場可分為五大類：小分子藥物、生物製藥、先進療法、疫苗和特殊製劑。小分子藥物因其成熟的生產流程和較低的複雜性而仍被廣泛應用，而生物製藥預計將在合約研發生產機構（CDMO）的需求中佔據重要地位，因為它們需要先進的技術、專業的設施和嚴格的監管合規性。與小分子藥物不同，單株抗體、重組蛋白和細胞療法等生物製藥難以在企業內大規模生產。像龍沙（Lonza）和三星生物製劑（Samsung Biologics）這樣的公司已在生物製藥生產能力方面投入巨資，這反映出它們對外包的高度依賴。包括美國FDA加速生物製藥核准計畫在內的政府舉措，進一步提升了生物製藥作為全球製藥生產戰略重點的地位。

醫藥CDMO市場—區域洞察

預計北美將在藥品合約研發生產（CDMO）市場中扮演重要角色，主要得益於政府和私營部門持續投資以增強國內藥品生產能力。美國食品藥物管理局（FDA）已啟動多項舉措，例如「預檢計畫」（PreCheck ）試驗計畫，旨在簡化監管核准，並加速全美各地新建藥品生產設施。這些措施與確保基本藥物的可靠供應、減少對進口的依賴、加強供應鏈穩定性以及支持擴大本地生產能力等國家優先事項相一致。

同時，各大製藥公司正在擴大在北美的製造地。例如，諾華計劃在德克薩斯州新建一座放射性配體療法製造地，作為其多設施擴建計畫的一部分。與此同時，艾伯維正在投資數億美元，擴大其在伊利諾伊州的原料藥（API）生產，這反映出業界對該地區生產能力以及政府獎勵充滿信心。這些投資不僅將創造就業機會，也顯示公共和企業策略規劃正在攜手合作，將北美打造成為先進製藥製造和合約研發生產力（CDMO）活動的中心。

韓國醫藥CDMO市場—國別分析

憑藉政府的定向支持和蓬勃發展的產業，韓國已成為全球醫藥CDMO生態系統的重要貢獻者。韓國政府已將包括疫苗、mRNA和蛋白質生產技術在內的生物製藥列為戰略領域，並將其視為加強長期成長和實現自主生產的關鍵國家優先事項之一。監管機構也考慮推出相關立法，以正式加強CDMO活動和出口生產的框架，這反映了韓國對醫藥創新和全球供應鏈的政策重點。

總部位於仁川松島的三星生物製劑公司，正透過與國際合作夥伴簽訂大規模生產合約以及持續擴大產能，不斷鞏固其作為韓國合約研發生產機構（CDMO）的地位。該公司預計到2025年銷售額將超過4.5兆韓元，並已獲得多項重要的多年期生產契約，這些契約支撐了對生物製藥服務的需求。新增工廠和先進生物製藥生產平台的策略性投資，進一步鞏固了韓國作為新興生物製造和合約研發服務中心的地位。

目錄

第1章：醫藥CDMO市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：醫藥CDMO的關鍵市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：醫藥CDMO產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：醫藥CDMO市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：醫藥CDMO市場現狀

  • 2024年醫藥CDMO市佔率分析
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 醫藥CDMO市場：依服務類型分類

  • 概述
    • 細分市場佔有率分析：依服務類型分類
    • 藥物開發服務
    • 分析和監管支持
    • 臨床生產
    • 商業生產
    • 包裝和序列化服務

第8章：醫藥CDMO市場：依技術分類

  • 概述
    • 細分市場佔有率分析：依技術分類
    • 化學合成和原料藥生產
    • 發酵和生物過程
    • 灌裝、精加工和無菌加工
    • 連續製造
    • 先進的分析技術

第9章：醫藥CDMO市場：依治療方式分類

  • 概述
    • 細分市場佔有率分析：依治療方式分類
    • 低分子化合物
    • 生物製藥
    • 先進的治療方法（細胞、基因、組織）
    • 疫苗
    • 特殊配方（例如，脂質體、奈米顆粒）

第10章：醫藥CDMO市場：依最終用途分類

  • 概述
    • 細分市場佔有率分析：依最終用途分類
    • 大型製藥企業
    • 中型生技公司
    • 虛擬製藥
    • 公共衛生計劃
    • 非營利研究聯盟

第11章：醫藥CDMO市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他中東和非洲國家

第12章：主要供應商分析：製藥CDMO產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Catalent
    • Thermo Fisher Scientific
    • Lonza Group
    • Recipharm AB
    • Samsung Biologics
    • WuXi AppTec
    • Cambrex Corporation
    • WuXi Biologics
    • Piramal Pharma Solutions
    • Corden Pharma International
    • Vetter Pharma
    • Eurofins CDMO
    • Others

第13章：分析師的綜合視角

簡介目錄
Product Code: ANV6159

Pharmaceutical CDMO Market size was valued at US$ 180,418.09 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.

Pharmaceutical Contract Development and Manufacturing Organization (CDMO) is a specialized service provider that supports pharmaceutical and biotechnology companies in developing, producing, and commercializing drugs. CDMOs offer services spanning drug formulation, process development, clinical and commercial manufacturing, analytical testing, and packaging. By partnering with CDMOs, companies gain access to advanced technologies, regulatory expertise, and flexible production capacity, enabling faster time-to-market and cost efficiency. Beyond service provision, CDMOs act as strategic collaborators, particularly for complex therapies such as biologics and gene therapies, fostering innovation, quality compliance, and sustainable growth. Governments and global agencies such as the U.S. FDA, European Medicines Agency, and World Health Organization gradually emphasize domestic manufacturing resilience and quality standards, inspiring CDMO engagement to strengthen supply chains, support vaccine capacity, and align with public health objectives worldwide.

Pharmaceutical CDMO Market- Market Dynamics

Rising demand for advanced biologic therapies to support long-term healthcare sustainability

The rising demand for advanced biologic therapies is a key catalyst for growth in pharmaceutical manufacturing and outsourcing because these therapies, such as monoclonal antibodies, recombinant proteins, vaccines, and cell-based treatments, are increasingly used to treat complex chronic conditions, including cancer, autoimmune diseases, and metabolic disorders. Pharmaceutical companies are expanding their biologics portfolios to meet this need, and regulators in major markets are facilitating this evolution. For instance, the U.S. Food and Drug Administration (FDA) has been actively adapting guidance to accelerate development and access to biosimilars and advanced biologic drugs, helping increase availability while managing costs for patients.

In response to this sustained demand, leading global manufacturers are investing in capacity expansion and strategic assets. South Korea's Samsung Biologics is expanding its presence in the United States by acquiring a Maryland production facility to support biologics output and meet long term demand. On the policy side, countries like India have announced major programmes to bolster biopharmaceutical capabilities, including a dedicated ₹10,000 crore initiative over five years to position the nation as a global hub for biologics and biosimilars manufacturing. These combined public and private commitments reflect how biologic therapies are shaping sustainable healthcare priorities worldwide.

Pharmaceutical CDMO Market- Segmentation Analysis:

The Global Pharmaceutical CDMO Market is segmented on the basis of Service Type, Technology, Therapeutic Modality, End-Use, and Region.

Based on service type market is divided into five categories: Drug Development Services, Analytical and Regulatory Support, Clinical Manufacturing, Commercial Manufacturing, and Packaging & Serialization Services. Commercial Manufacturing act as a central role in the market because it delivers the large scale production capacity that sponsors most urgently need once drugs clear clinical development. Companies like Lonza have shown this segment's importance: in 2025, its core CDMO business - heavily weighted toward commercial manufacturing across small molecule and biologics platforms - grew to CHF 6.5 billion in sales, accounting for a substantial portion of overall revenue and driving expanded margins. Government continuous efforts, such as the U.S. FDA's PreCheck initiative, also reinforce the priority of scaling domestic manufacturing by streamlining facility reviews and enhancing production infrastructure, underscoring commercial manufacturing's pivotal role in supporting reliable supply and market access.

The market is divided into five categories based on therapeutic modality: Small Molecules, Biologic Molecules, Advanced Therapies, Vaccines, and Specialized Formulations. While Small Molecules remain widely used due to established manufacturing processes and lower complexity, Biologic Molecules are expected to play a key role in CDMO demand because they require advanced technologies, specialized facilities, and strict regulatory compliance. Unlike small molecules, biologics such as monoclonal antibodies, recombinant proteins, and cell-based therapies cannot be produced easily at scale in-house. Companies like Lonza and Samsung Biologics invest heavily in biologics manufacturing capacity, reflecting higher outsourcing reliance. Government initiatives, including the U.S. FDA's accelerated biologics approval programs, further reinforce the focus on biologics as a strategic priority in global pharmaceutical manufacturing.

Pharmaceutical CDMO Market- Geographical Insights

North America is expected to play a key role in the Pharmaceutical CDMO market, driven by continued investments from both the government and private sectors to enhance domestic drug production capabilities. The U.S. Food and Drug Administration (FDA) has launched programs such as the PreCheck Pilot Program, which aims to simplify regulatory approvals and expedite the development of new pharmaceutical manufacturing facilities across the United States. These efforts reduce dependence on imports, strengthen supply chain stability, and support the expansion of local manufacturing capacity, in line with national priorities to ensure reliable access to essential medicines.

In parallel, major pharmaceutical companies are increasing their North American manufacturing footprint. For example, Novartis plans to build a new radioligand therapy manufacturing site in Texas as part of a multi-facility expansion, while AbbVie is investing hundreds of millions of dollars to expand API manufacturing in Illinois, reflecting industry confidence in regional capabilities and government incentives for domestic production. These investments not only create employment but also demonstrate how public policy and corporate strategic planning are converging to position North America as a central hub for advanced pharmaceutical manufacturing and CDMO activities.

South Korea Pharmaceutical CDMO Market- Country Insights

South Korea has positioned itself as a significant contributor to the global Pharmaceutical CDMO ecosystem through targeted government support and dynamic industry advancement. The South Korean government has identified biopharmaceuticals as a strategic sector, including technologies for vaccines, mRNA, and protein production, among key national priorities to bolster long term growth and self-reliance. Regulatory authorities are also considering supportive legislation to formally enhance CDMO activities and export manufacturing frameworks, reflecting policy emphasis on pharmaceutical innovation and global supply chains.

At the corporate level, Samsung Biologics, headquartered in Songdo, Incheon, demonstrates South Korea's growing CDMO stature, with substantial manufacturing contracts with international partners and ongoing capacity expansions. The company reported revenues above 4.5 trillion Korean won in 2025 and has secured significant multi-year manufacturing agreements that underline demand for its biopharmaceutical services. Its strategic investments in additional plants and advanced biologics production platforms further reinforce South Korea's role as an emerging hub for biomanufacturing and contract development services.

Pharmaceutical CDMO Market- Competitive Landscape:

The Pharmaceutical CDMO market is highly competitive, comprising global leaders and specialized regional providers offering end-to-end drug development and manufacturing services. Companies compete based on technical expertise, regulatory compliance, manufacturing capacity, quality standards, and time-to-market efficiency. Leading players focus on expanding production facilities, investing in biologics and advanced therapy capabilities, and enhancing analytical and regulatory services. Strategic approaches such as mergers and acquisitions, long-term partnerships with pharmaceutical sponsors, new service launches, and geographic expansion are commonly employed to strengthen market presence. Firms like Lonza, Samsung Biologics, and Catalent exemplify these strategies, reinforcing their global leadership and client reach

Recent Developments:

In January 2026, Zydus completed the establishment of Zylidac Bio LLC, solidifying its U.S. biologics CDMO presence and aligning with regulatory trends supporting secure domestic manufacturing, thereby improving service availability for global biopharmaceutical partners.

In September 2025, Terumo Corporation acquired a drug product plant and quality control operations from WuXi Biologics in Leverkusen, Germany, enhancing its production scale and quality control capabilities for serving both local and international pharmaceutical customers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PHARMACEUTICAL CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Catalent
  • Thermo Fisher Scientific
  • Lonza Group
  • Recipharm AB
  • Samsung Biologics
  • WuXi AppTec
  • Cambrex Corporation
  • WuXi Biologics
  • Piramal Pharma Solutions
  • Corden Pharma International
  • Vetter Pharma
  • Eurofins CDMO
  • Others

GLOBAL PHARMACEUTICAL CDMO MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Drug Development Services
  • Analytical and Regulatory Support
  • Clinical Manufacturing
  • Commercial Manufacturing
  • Packaging & Serialization Services

GLOBAL PHARMACEUTICAL CDMO MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

  • Chemical Synthesis & API Manufacturing
  • Fermentation & Bioprocessing
  • Fill-Finish & Aseptic Processing
  • Continuous Manufacturing
  • Advanced Analytical Technologies

GLOBAL PHARMACEUTICAL CDMO MARKET, BY THERAPEUTIC MODALITY- MARKET ANALYSIS, 2019 - 2032

  • Small Molecules
  • Biologic Molecules
  • Advanced Therapies (Cell, Gene, and Tissue)
  • Vaccines
  • Specialized Formulations (e.g., liposomal, nanoparticle)

GLOBAL PHARMACEUTICAL CDMO MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032

  • Large Pharmaceutical Companies
  • Mid-Size Biotech Firms
  • Virtual Pharma
  • Public Health Programs
  • Non-Profit Research Consortia

GLOBAL PHARMACEUTICAL CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Pharmaceutical CDMO Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Pharmaceutical CDMO Market Snippet by Service Type
    • 2.1.2. Pharmaceutical CDMO Market Snippet by Technology
    • 2.1.3. Pharmaceutical CDMO Market Snippet by Therapeutic Modality
    • 2.1.4. Pharmaceutical CDMO Market Snippet by End-Use
    • 2.1.5. Pharmaceutical CDMO Market Snippet by Country
    • 2.1.6. Pharmaceutical CDMO Market Snippet by Region
  • 2.2. Competitive Insights

3. Pharmaceutical CDMO Key Market Trends

  • 3.1. Pharmaceutical CDMO Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Pharmaceutical CDMO Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Pharmaceutical CDMO Market Opportunities
  • 3.4. Pharmaceutical CDMO Market Future Trends

4. Pharmaceutical CDMO Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Pharmaceutical CDMO Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Pharmaceutical CDMO Market Landscape

  • 6.1. Pharmaceutical CDMO Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Pharmaceutical CDMO Market - By Service Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Service Type, 2024 & 2032 (%)
    • 7.1.2. Drug Development Services
    • 7.1.3. Analytical and Regulatory Support
    • 7.1.4. Clinical Manufacturing
    • 7.1.5. Commercial Manufacturing
    • 7.1.6. Packaging & Serialization Services

8. Pharmaceutical CDMO Market - By Technology

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
    • 8.1.2. Chemical Synthesis & API Manufacturing
    • 8.1.3. Fermentation & Bioprocessing
    • 8.1.4. Fill Finish & Aseptic Processing
    • 8.1.5. Continuous Manufacturing
    • 8.1.6. Advanced Analytical Technologies

9. Pharmaceutical CDMO Market - By Therapeutic Modality

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Therapeutic Modality, 2024 & 2032 (%)
    • 9.1.2. Small Molecules
    • 9.1.3. Biologic Molecules
    • 9.1.4. Advanced Therapies (Cell, Gene, and Tissue)
    • 9.1.5. Vaccines
    • 9.1.6. Specialized Formulations (e.g., liposomal, nanoparticle)

10. Pharmaceutical CDMO Market - By End-Use

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
    • 10.1.2. Large Pharmaceutical Companies
    • 10.1.3. Mid Size Biotech Firms
    • 10.1.4. Virtual Pharma
    • 10.1.5. Public Health Programs
    • 10.1.6. Non Profit Research Consortia

11. Pharmaceutical CDMO Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Pharmaceutical CDMO Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Pharmaceutical CDMO Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Pharmaceutical CDMO Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Pharmaceutical CDMO Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Pharmaceutical CDMO Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Therapeutic Modality, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Pharmaceutical CDMO Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Catalent
    • 12.2.2. Thermo Fisher Scientific
    • 12.2.3. Lonza Group
    • 12.2.4. Recipharm AB
    • 12.2.5. Samsung Biologics
    • 12.2.6. WuXi AppTec
    • 12.2.7. Cambrex Corporation
    • 12.2.8. WuXi Biologics
    • 12.2.9. Piramal Pharma Solutions
    • 12.2.10. Corden Pharma International
    • 12.2.11. Vetter Pharma
    • 12.2.12. Eurofins CDMO
    • 12.2.13. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us